

Davidson, Mark

From: Davidson, Mark
Sent: Monday, April 24, 2017 11:02 AM
To: 'Rizwana Sproule'
Cc: 'Alex Babayan'
Subject: BLA 125643/.0.7 Submission: Clinical Request for Information -regarding response A
Attachments: KITE Clinical IR 2, 4-24-17.docx

Hi Dr. Sproule,

We have a follow up request for information for Clinical IR Part A received April 21, 2017. Please see attached.

Please try to respond by 2:00pm Wednesday, April 26, 2017.

Thank You

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."